Sugi Predict

Sugi Predict / Compounds / SCHEMBL1270133

SCHEMBL1270133

SCHEMBL1270133

Cc1cnc(NC(=O)c2ccccc2)s1

nearest known ligand 0.75

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 5/20 0.75
▸ NPC1 O15118 9/20 0.68
▸ RAB9A P51151 9/20 0.68
▸ PKM P14618 5/20 0.68
▸ KDR P35968 1/20 0.68
▸ CCNE1 P24864 1/20 0.67
▸ CDK2 P24941 1/20 0.67
▸ CDK5 Q00535 1/20 0.67
▸ MEN1 O00255 2/20 0.65
▸ KMT2A Q03164 2/20 0.65
▸ POLB P06746 1/20 0.65
▸ SCD O00767 1/20 0.61
▸ TP53 P04637 2/20 0.60
▸ ALDH1A1 P00352 2/20 0.60
▸ TSHR P16473 1/20 0.60
▸ LMNA P02545 2/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL233270 0.87 SMN1; SMN2 (0.75) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL2629279 0.86 SMN1; SMN2 (1.00) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL8554959 0.85 RAB9A (0.70) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL8557237 0.84 SMN1; SMN2 (0.71) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL10253092 0.84 SMN1; SMN2 (0.71) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL16594526 0.84 SMN1; SMN2 (0.71) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL4290502 0.84 SMN1; SMN2 (0.71) SMN1; SMN2NPC1RAB9APKMMEN1
SCHEMBL7352140 0.83 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9APKMKDR
SCHEMBL8125122 0.83 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9APKMKDR
SCHEMBL1353749 0.83 SMN1; SMN2 (0.60) SMN1; SMN2NPC1RAB9APKMKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2459554-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS Cadila Healthcare Limited (IN) 2012-06-06 — — EP claimed
EP-2445908-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS Cadila Healthcare Limited (IN) 2012-05-02 — — EP claimed
WO-2011013141-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2011-02-03 — — WO claimed
WO-2010150280-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2010-12-29 — — WO claimed
EP-1576093-A4 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS INC (US) 2009-07-08 — — EP claimed
EP-1576093-A2 3-DEOXYGLUCOSONE AND SKIN Dynamis Therapeutics, Inc. (US) 2005-09-21 — — EP claimed
WO-2003089601-A2 3-DEOXYGLUCOSONE AND SKIN DYNAMIS THERAPEUTICS, INC. (US) 2003-10-30 — — WO claimed
CN-110256418-A The benzamide that 1,3- thiazol-2-yl replaces 拜耳公司 2019-09-20 — — CN disclosed
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. 2017-08-03 — — US disclosed
US-9273077-B2 Phosphorus derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2016-03-01 — — US disclosed
WO-2016004272-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE PHARMACYCLICS LLC (US) 2016-01-07 — — WO disclosed
US-20150225436-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2015-08-13 — — US disclosed
US-9012462-B2 Phosphorous derivatives as kinase inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2015-04-21 — — US disclosed
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 — — US disclosed
US-20130225527-A1 Phosphorus Derivatives as Kinase Inhibitors ARIAD PHARMACEUTICALS, INC. (US) 2013-08-29 — — US disclosed
EP-2459554-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS Cadila Healthcare Limited (IN) 2012-06-06 — — EP disclosed
EP-2445908-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS Cadila Healthcare Limited (IN) 2012-05-02 — — EP disclosed
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ARIAD PHARMACEUTICALS, INC. (US) 2011-12-01 — — US disclosed
WO-2011013141-A2 SUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2011-02-03 — — WO disclosed
WO-2010150280-A1 DISUBSTITUTED BENZAMIDE DERIVATIVES AS GLUCOKINASE (GK) ACTIVATORS CADILA HEALTHCARE LIMITED (IN) 2010-12-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170218000-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 SMN1; SMN2 4512/4885NPC1 3672/4885RAB9A 1513/4885
US-20150225436-A1 PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS MAP3K6, PIK3CA, MAP3K20 SMN1; SMN2 4628/4885NPC1 3877/4885RAB9A 1490/4885
US-20110294806-A1 AZAINDOLE DERIVATIVES AS KINASE INHIBITORS ABL1, CDKN1A, MAP3K13 SMN1; SMN2 4363/4885NPC1 4114/4885RAB9A 1616/4885
US-20130225527-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 SMN1; SMN2 4789/4885NPC1 3834/4885RAB9A 2334/4885
US-20130225528-A1 Phosphorus Derivatives as Kinase Inhibitors PHKA1, PIK3CA, PHKA2 SMN1; SMN2 4789/4885NPC1 3834/4885RAB9A 2334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.